Quirós, Luis Pastor, and Rocío Ugalde. 2019. “Analysis of the Budgetary Impact of Alemtuzumab As Second-Line Therapy, Compared to Natalizumab and Fingolimod, in Patients Previously Treated With Interferon Beta 1b, Diagnosed With Active Relapsing-Remitting Multiple Sclerosis, Treated in the Costa Rican Social Security Fund”. Global and Regional Health Technology Assessment 6 (1). https://doi.org/10.33393/grhta.2019.467.